Survival of Australian women with invasive epithelial ovarian cancer: A populationbased study

Medical Journal of Australia

Volumn 201, Issue 5, 2014, Pages 283-288

  Anuradha, Satyamurthy ^a   Webb, Penelope M ^a   Blomfield, Penny ^b   Brand, Alison H ^c   Friedlander, Michael ^d   Leung, Yee ^e   Obermair, Andreas ^f   Oehler, Martin K ^g   Quinn, Michael ^h   Steer, Christopher ⁱ   Jordan, Susan J ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ Border Medical Oncology Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ASCITES; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CHARLSON COMORBIDITY INDEX; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; COMORBIDITY; FEMALE; GEOGRAPHY; HAZARD RATIO; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVARY CARCINOMA; POPULATION RESEARCH; RURAL AREA; SOCIOECONOMICS; SURVIVAL RATE; URBAN AREA; VERY ELDERLY; AUSTRALIA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; SUBURBAN POPULATION;

AGE FACTORS; AGED; ASCITES; AUSTRALIA; COMORBIDITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RURAL POPULATION; SOCIOECONOMIC FACTORS; SUBURBAN POPULATION;

EID: 84907352401     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.00132     Document Type: Article

References (27)

1. Australian Institute of Health and Welfare, Cancer Australia. Gynaecological cancers in Australia: an overview. Canberra: AIHW, 2012. (AIHW Cat. No. CAN 66; Cancer Series No. 70.) http://www.aihw.gov.au/publicationdetail/?id=10737422954 (accessed Apr 2014).
2. Laurvick CL, Semmens JB, Holman CD, Leung Y.C. Ovarian cancer in Western Australia (1982-98): incidence, mortality and survival. Aust N Z J Public Health 2003; 27: 588-595.
3. Grossi M, Quinn MA, Thursfield VJ, et al. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust 2002; 177: 11-16.
4. Choi M, Fuller CD, Thomas CR Jr, Wang S.J. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol 2008; 109: 203-209.
5. Jordan S, Steer C, DeFazio A, et al. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study. Gynecol Oncol 2013; 129: 310-317.
6. Australian Institute of Health and Welfare. Rural, regional and remote health: a guide to remoteness classification. Canberra: AIHW, 2004. (AIHW Cat. No. PHE 53; Rural Health Series No. 4.) http://www.aihw.gov.au/publication-detail/?id=6442467589 (accessed Apr 2014).
7. Australian Bureau of Statistics. Information paper: census of population and housing. Socio-Economic Indexes for Areas, Australia 2001. Canberra: ABS, 2003. (ABS Cat. No. 2039.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/2039.02001?OpenDocument (accessed May 2014).
8. Charlson ME, Pompei P, Ales KL, MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
9. Merritt MA, Green AC, Nagle CM, Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group. Talcum powder, chronic pelvic infl ammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008; 122: 170-176.
10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
11. Office for National Statistics. Cancer survival rates, cancer survival in England, patients diagnosed 2005-2009 and followed up to 2010. London: ONS, 2011. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-239726 (accessed May 2014).
12. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics 2013. Toronto: Canadian Cancer Society, 2013. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadiancancer-statistics-2013-EN.pdf (accessed Jun 2014).
13. Monitoring of cancer incidence in Japan-survival 2003-2005 report. Tokyo: Center for Cancer Control and Information Services, National Cancer Center, 2013. http://ganjoho.jp/pro/statistics/en/table_download.html (accessed Jun 2014).
14. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries. Version 6.1 (25.04.2014). Copenhagen: Association of the Nordic Cancer Registries, Danish Cancer Society 2014. http://www.ancr.nu (accessed May 2014).
15. O'Malley CD, Cress RD, Campleman SL, Leiserowitz G.S. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 2003; 91: 608-615.
16. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003; 101 (5 Pt 1): 885-891.
17. Yang L, Klint A, Lambe M, et al. Predictors of ovarian cancer survival: a population-based prospective study in Sweden. Int J Cancer 2008; 123: 672-679.
18. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82: 893-901.
19. Rauh-Hain JA, Diver EJ, Clemmer JT, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 2013; 131: 46-51.
20. Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004; 100: 2148-2153.
21. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370-376.
22. Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer 2008; 8: 252.
23. Puls LE, Duniho T, Hunter JE, et al. The prognostic implication of ascites in advancedstage ovarian cancer. Gynecol Oncol 1996; 61: 109-112.
24. Tetsche MS, Nørgaard M, Jacobsen J, et al. Comorbidity and ovarian cancer survival in Denmark, 1995-2005: a population-based cohort study. Int J Gynecol Cancer 2008; 18: 421-427.
25. Maas HA, Kruitwagen RF, Lemmens VE, et al. The infl uence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 2005; 97: 104-109.
26. Coory MD, Ho T, Jordan S.J. Australia is continuing to make progress against cancer, but the regional and remote disadvantage remains. Med J Aust 2013; 199: 605-6 08.
27. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer survival in Australia 1992-1997: geographic categories and socioeconomic status. Canberra: AIHW, 2003. (AIHW Cat. No. CAN 17; Cancer Series No. 22.) http://www.aihw.gov.au/publication-detail/?id=6442467451 (accessed Apr 2014).